Is the price fair?
What LH's price assumes
Labcorp trades at 29.7× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
29.7
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 1.56
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.6%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +2.0%
Growth the price implies · The price pays for +2.0% free cash flow growth a year for a decade; the business has delivered +1.3% a year over the last three.
Details›
- Price / book2026-Q1
- 2.53
- EV / EBIT2026-Q1
- 18.7
- EV / sales2026-Q1
- 1.90
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $1.38B
- Market capitalisation
- $21.0B
- 3-year revenue growth
- +6.3%
- 3-year free cash flow growth
- +1.3%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $137.09 |
| Its own P/E history, median | $187.54 |
| Its own P/E history, upper quartile | $293.58 |
| 52-week range | $244.69 – $339.57 |
| Today | $335.71 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #22 of 29 by Smart Score